Same ingredient, two names · tirzepatide
Mounjaro vs Zepbound
From the two FDA labels, read Published by PepVault
Mounjaro and Zepbound are the same medicine, tirzepatide, under two names from Eli Lilly.
What differs is the label. FDA approved Mounjaro for blood sugar control in type 2 diabetes from age 10, and lowering heart risk in adults with type 2 diabetes. Zepbound is approved for weight loss and keeping it off, and obstructive sleep apnea in adults with obesity.
Label against label
| Compared | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | tirzepatide | tirzepatide |
| Class | GIP and GLP-1 receptor agonist | GIP and GLP-1 receptor agonist |
| Maker | Eli Lilly | Eli Lilly |
| Approved for | Type 2 diabetes (adults and children 10 and up); heart risk | Weight reduction; obstructive sleep apnea with obesity |
| Forms | Single-dose pen or vial; Multi-dose vial or KwikPen | Single-dose pen or vial; Multi-dose vial or KwikPen |
| How often | once a week | once a week |
| Starting dose | 2.5 mg a week | 2.5 mg a week |
| Top dose on the label | 15 mg a week | 15 mg a week |
| Most reported side effect | Nausea, 18% on 15 mg (placebo 4%) | Nausea, 28% on 15 mg (placebo 8%) |
| Boxed warning | “RISK OF THYROID C-CELL TUMORS” | “RISK OF THYROID C-CELL TUMORS” |
| First approved | 2022 | 2023 |
Each label’s side-effect figure comes from its own trials, at its own doses and in its own patients; as the labels themselves say, rates from different trials can’t be compared directly.
The two dosing schedules
This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.
Mounjaro, once a week
Zepbound, once a week

A missed dose, on each label
- Mounjaro: A missed Mounjaro dose can still be given within 4 days (96 hours). After that it is skipped and the next one comes on the usual day.
- Zepbound: Zepbound’s missed-dose rule gives 4 days (96 hours): within that window the dose is taken as soon as possible; after it, the dose is skipped and the week carries on as usual.
The research on the ingredient
Questions
Are Mounjaro and Zepbound the same drug?
They hold the same active ingredient, tirzepatide, from Eli Lilly. They are approved for different uses and come in different forms and doses.
What are Mounjaro and Zepbound approved for?
Mounjaro is approved for blood sugar control in type 2 diabetes from age 10, and lowering heart risk in adults with type 2 diabetes. Zepbound is approved for weight loss and keeping it off, and obstructive sleep apnea in adults with obesity.
How often are Mounjaro and Zepbound taken?
Mounjaro is taken once a week, as an injection; Zepbound once a week, as an injection.
What are the dose ranges of Mounjaro and Zepbound?
On their labels, Mounjaro runs 2.5 mg to 15 mg once a week, and Zepbound 2.5 mg to 15 mg once a week. A prescriber sets the actual dose.
What is the most common side effect of Mounjaro and Zepbound?
On Mounjaro’s label: nausea, 18% on 15 mg (placebo 4%). On Zepbound’s: nausea, 28% on 15 mg (placebo 8%).
Sources
- MOUNJARO (tirzepatide) injection, for subcutaneous use, FDA label on DailyMed (version 40, published Sep 2, 2026; read Nov 18, 2026)
- ZEPBOUND (tirzepatide) injection, for subcutaneous use, FDA label on DailyMed (version 40, published Sep 2, 2026; read Nov 18, 2026)
- Drugs@FDA, NDA 215866 (Mounjaro, the injection; application first approved 2022)
- Drugs@FDA, NDA 217806 (Zepbound, the injection; application first approved 2023)
PepVault is not affiliated with Eli Lilly. Mounjaro is a trademark of its owner. Zepbound is a trademark of its owner.